Seasonal Influenza Vaccines
Global Forecast
The independent global influenza vaccine demand model -48 countries, all major manufacturers, mRNA landscape and a new decade outlook to 2040. Now tracking CSL Seqirus' Aujemflu through EU CHMP opinion, UK MHRA approval and JCVI's 2027/28 advice as it lands. The market is larger and more contested than the headlines suggest.
- Previous edition
- July 2024
- Format
- MS Excel + presentation
- Countries modelled
- 48
- Forecast horizon
- To 2040
- Manufacturers covered
- All major players
- mRNA section
- Yes - revised
- Aujemflu milestones
- Tracked to Jul 2026
globally, 2025
value, 2025
modelled
outlook added
Six dimensions - one model
The May 2026 edition is a major refresh of the VacZine Analytics influenza model, covering current market dynamics, manufacturer strategies, mRNA pipeline and - for the first time - a complete decade outlook to 2040.
48-country volume and value model spanning USA, Canada, EU, and 37 emerging/ROW markets including PAHO nations. Dose and revenue outputs by region, fully validated against manufacturer-reported revenues.
Sanofi, CSL Seqirus, GSK and ModernaTX analysed in depth - revenue trends, pricing strategy, pipeline progression and positioning, including CSL's newly-approved Aujemflu (adjuvanted, cell-based, 50+) and its EU/UK regulatory path. Who is gaining share and who is under pressure.
The mRNA opportunity has been substantially re-scoped since 2024. The model details why, what it means for total market value to 2030 and which programmes still hold commercial promise.
CD388/MK-1406 (Merck & Cidara) and universal vaccine approaches assessed for their capacity to reshape the prevention market - not just redistribute it. A key upside scenario not yet in the base case.
First edition to model the full 2031-2040 window. Where combination and mRNA vaccines are assumed to finally gain traction. Global CAGR and USA value trajectory fully modelled.
Four key risks assessed: US coverage suppression under RFK Jr. environment, mRNA pricing resistance ex-US, payor burden from concurrent innovation and the CD388 Phase 3 upside. Transparent methodology.
The biggest forecast revision in the model's history
Between July 2024 and May 2026, the global market outlook shifted materially. The 2030 global market value has been cut by over $3bn - and the model explains exactly why, and what the implications are for commercial strategy.
The mRNA hypothesis that drove the prior estimate has not materialised on schedule.
USA market - estimated 2025 revenue share
USA FY2025/26 season estimates. Full country-level value and volume outputs in the licensed model.
Aujemflu clears the EU and UK gauntlet - JCVI advice locks in a 2027/28 launch
CSL Seqirus' Aujemflu - a trivalent, adjuvanted, cell-culture influenza vaccine (aIIVc) for adults 50 and over - has moved through four regulatory, advisory and commercial milestones since June 2026. The model captures each one and what it means for CSL's positioning against Fluad and Sanofi's HD franchise.
Seqirus UK Limited granted UK approval for adults aged 50 and over - CSL's first adjuvanted, cell-based authorisation for a seasonal (non-pandemic) indication in a major regulated market.
CSL Seqirus and UKHSA extended their pandemic-preparedness Advance Purchase Agreement through 2031, covering 100m+ pandemic influenza doses from the Liverpool site, and confirmed the UK will be the first country worldwide to roll out Aujemflu - from the 2027/28 season, for adults 65+ and at-risk 50-64s.
EMA's CHMP recommended EU-wide marketing authorisation for adults 50+, based on a 7,699-subject trial showing a stronger immune response than a quadrivalent adjuvanted egg-based comparator. Formal EC decision typically follows within ~2 months of CHMP opinion - due imminently.
JCVI named Aujemflu (aIIVc) a preferred option for adults 65+ and for 50-64s in a clinical risk group, alongside aIIV, IIVc, IIV-HD and IIVr. First eligible UK procurement season is 2027/28, not 2026/27.
JCVI reviewed Moderna's quadrivalent mRNA candidate alongside Aujemflu but judged it unlikely to be procurement-ready for 2027/28 - pushing the UK's first mRNA-flu decision point further out and handing CSL a clearer near-term runway.
The market is moving - in more than one direction
The May 2026 model covers a market under simultaneous pressure from volume contraction, policy headwinds, mRNA delay and the first credible disruptor technologies in decades.
US volume contracted 23% since 2021/22 - but value held
Distributed doses fell to ~132m in early 2025 from 145m a year earlier. Yet pricing strategy by Sanofi and CSL Seqirus protected aggregate value. The model breaks this apart market by market.
Sanofi exited. CSL quietly shelved. Moderna persisted. GSK now enters Phase 3.
The mRNA landscape is no longer a three-way split. On 1 Sep 2026 GSK announced it will advance its mRNA candidate FLUm3HA.b-3NA - targeting both haemagglutinin and neuraminidase - into Phase 3 after Phase II data showed higher immune responses than licensed standard- and high-dose inactivated comparators in adults 18+. It is the first Phase 3 trial of a dual-antigen (HA+NA) mRNA flu vaccine, adding a fourth mRNA contender alongside Moderna's marketed mFLUSIVA, Sanofi/Novavax's protein-combo pivot and CSL's continued silence. The full commercial implications are modelled.
The cell-based vs egg-based battle is accelerating
CSL Seqirus is sunsetting its egg-based Afluria-TIV while expanding Flucelvax globally. Flucelvax private list price: $43.54/dose for 2026/27 - a widening premium over egg-based standard TIVs at ~$20-21. Aujemflu, CSL's new adjuvanted cell-based vaccine for 50+, adds a second cell-based flank - MHRA and CHMP sign-off secured mid-2026, JCVI advising its use from 2027/28.
RFK Jr. & BARDA cuts - a structural headwind not yet in most models
HHS anti-vaccine environment and BARDA mRNA funding cancellations represent a structural risk to US coverage rates in 2026/27 and beyond. This edition explicitly assesses the scenario - and its limits.
FLUNITY-HD: first vaccine to show superior hospitalisation protection in 65+
Sanofi's Fluzone-HD/Efluelda® Lancet data (October 2025) is a landmark result. The model assesses whether this data is enough to unlock JCVI preference in the UK and reinforce premium pricing in Germany. That German/French marketing push triggered formal EU antitrust scrutiny - the European Commission opened proceedings on 26 June 2026 over claims Sanofi's campaign disparaged CSL's Fluad, and on 14 Oct 2026 accepted Sanofi's commitments and made them legally binding, closing the case without a fine. Sanofi must avoid disparaging Fluad in German/French HCP marketing through March 2030 and state on its websites for two years that national bodies treat Efluelda and Fluad as equivalent. A reminder that HD/adjuvanted 65+ share gains now carry competition-law risk alongside clinical differentiation.
CD388/MK-1406: Merck says up to $5bn - we model the scenario
Cidara/Merck's drug-Fc conjugate targeting neuraminidase enters Phase 3 (ANCHOR study). With combined efficacy of 60-90%, it could expand the total prevention market. Phase 3 primary data expected H2 2026.
Sanofi-Novavax flu/COVID combo hits Phase 3 - $125m milestone triggered
On 29 Oct 2026, Novavax confirmed Sanofi had dosed the fifth participant in a European Phase 3 trial combining Novavax's Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose in adults 60+, triggering a $125m milestone payment under their licensing agreement. A further $75m is due on manufacturing tech transfer (expected mid-2027) and $225m on a US combination-vaccine launch - the clearest sign yet of a credible flu/COVID combo route to market.
A glimpse of the model output
The table below shows a partial view of regional volume and value. Country-level detail, manufacturer splits and scenario outputs are in the licensed Excel model.
| Region | Doses 2025 (est.) | Share of global vol. | Market value 2025 | 2030 forecast |
|---|---|---|---|---|
| USA | ~133m | 21% | $2.98bn | $5.45bn (base) |
| West (ex-USA) | ~119m | 18% | $1.42bn (EU11) | Modelled |
| ROW (37 nations + PAHO) | ~391m | 61% | Modelled | Modelled |
| Brazil breakdown | ██m | ██% | $██m | $██m |
| China (recalibrated) | ██m | ██% | +$200m adj. | $██m |
| Japan (recalibrated) | ██m | ██% | $██m | $██m |
| mRNA penetration - USA | - | - | Start yr: 2026 | ~~1.0% penetration |
What you receive
The licensed model is a decision-ready intelligence tool - not a static report. All outputs are formula-driven and scenario-ready.
- MS Excel demand model -48-country volume and value outputs, manufacturer revenue splits, regional breakdowns and scenario toggles
- mRNA scenario module - base, upside and conservative mRNA penetration assumptions for the USA and ex-US markets through 2030 and 2040
- Manufacturer intelligence section - Sanofi, CSL Seqirus, GSK and ModernaTX pipeline, pricing and strategy assessed and ranked
- Disruptor product analysis - CD388/MK-1406 (Merck/Cidara) and OVX836 (Osivax/Meiji) modelled as separate upside scenario
- New 2031-2040 decade model - first edition to extend the outlook to 2040, with CAGR analysis by region and manufacturer type
- Executive presentation - PowerPoint deck covering key storylines, charts and strategic commentary; supplied alongside the Excel workbook
- VacZine Analytics briefing call - available on request to walk through findings and answer client-specific questions
Built for organisations making real commercial decisions in influenza
The May 2026 edition is most valuable to teams that need to reconcile the mRNA delay, the disruptor pipeline and the shifting manufacturer landscape into a coherent forecast position.
Vaccine manufacturers
Competitive benchmarking, pricing strategy and country-level opportunity assessment across 48 markets.
Corporate strategy & BD
Validate investment theses around mRNA, combination vaccines and disruptor products against an independent model.
R&D & pipeline leadership
Understand whether mRNA differentiation - or a cell-based / adjuvanted strategy - is the more defensible near-term commercial position.
Investors & analysts
Independent validation of manufacturer revenue trajectories and realistic mRNA penetration assumptions for influenza specifically.
Procurement & health authorities
Understanding the competitive supply landscape, pricing dynamics and pipeline maturity for national procurement planning.
Market access & HEOR
Competitive context for payer dossiers - particularly for HD, cell-based and mRNA premium positioning arguments.
The VacZine Analytics seasonal influenza model has been maintained continuously since 2007, making it one of the longest-running independent demand models in vaccine market intelligence. The May 2026 edition represents the most substantial revision in the model's history - driven by mRNA delays, manufacturer strategy pivots and the arrival of credible disruptor technologies.
All outputs are validated against manufacturer-reported revenues. The model is built and maintained by VacZine Analytics' own analysts - not aggregated from third-party databases. For enquiries about methodology or a sample, contact us directly.
License the May 2026 edition
Contact VacZine Analytics for pricing, sample data and licensing terms. Single-licence and multi-user options available. Briefing calls included.